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Abstract
Background: Percutaneous tricuspid repair using the edge-to-edge technique is a novel treatment op-
tion. More data are needed to better understand which aspects predict a favorable outcome 
Methods: Twenty high-risk patients (78.6 ± 8.3 years, EuroScore II 9.1 ± 7.7%, STS score 8.8 ± 4.3)  
with severe symptomatic tricuspid regurgitation (TR) were treated with the MitraClip® system. All pa-
tients underwent standardized pre-, peri-, and post-procedural evaluation. Acute success was defined 
as successful edge-to-edge repair with TR reduction of ≥ 1 grade and survival until hospital discharge. 
Results: Fifteen (75%) patients showed acute success until discharge and 12 (60%) at 30-day follow-
up. In 5 (25%) patients repair failed due to either unsuccessful clip implantation (n = 2), single leaflet 
device attachment (n = 1), TR reduction < 1 grade (n = 1), or in-hospital death (n = 1). Comparing 
patients with successful procedure versus those with failed repair revealed similar comorbidities but 
more severe right heart failure, lower left ventricular ejection fraction, worse renal function, and higher 
diuretic equivalent doses in the failed repair group. No differences in conventional echocardiographic 
parameters for TR severity but more dilated tricuspid annulus geometry (tricuspid valve annulus, co-
aptation depth, tenting area) in the failed repair group were observed. The success rate of non-central/ 
/non-anteroseptal jet location was only 25%.
Conclusions: Tricuspid annulus geometry assessment may be of crucial importance and seems to im-
pact procedural outcomes in patients undergoing edge-to-edge tricuspid valve repair. Further investiga-
tions including advanced imaging are needed to better understand and treat this complex valve disease. 
(Cardiol J 2021; 28, 4: 579–588)
Key words: tricuspid regurgitation, percutaneous repair, transcatheter treatment,  
edge-to-edge technique, echocardiography
Introduction
Current guidelines reserve surgical treat-
ment of severe tricuspid regurgitation (TR) almost 
exclusively to combined left-heart procedures, 
whereas indications for stand-alone surgery for 
severe TR are only vaguely described [1–3]. The 
tricuspid valve (TV) is commonly referred to as 
“the forgotten valve” because data on single TV 
surgery are sparse, randomized trials are lacking, 
and there are no definite criteria guiding indica-
tion and timing of TV repair [4–6]. TV disease is 
mainly of secondary nature due to left-sided heart 
disease, pulmonary hypertension, atrial fibrillation, 
or lead-related problems in patients with cardiac 
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anatomy and pathogenic mechanisms of TR are 
complex and involve various degrees of right heart 
remodeling and tricuspid annulus dysfunction. 
Echocardiographic grading of TR severity has limi-
tations and seems insufficient despite introduction 
of a 5-stage grading scheme in 2017 with expansion 
of the ‘severe’ grade into three subcategories [10]. 
Recently, a more integrated approach for evaluation 
of TR disease has been proposed [7, 11].
Patients with severe TR often represent 
a high-risk surgical population, which relies at 
least partly on late referral and advanced heart 
failure (HF) after left-sided heart surgery [12]. 
The prognosis of functional tricuspid regurgitation 
(FTR) is poor [13–15]. Benfari et al. [13] recently 
reported a 5-year survival of 34% and a 10-year 
survival of only 14% for patients with severe FTR 
and HF with reduced ejection fraction (HFrEF). Im-
portantly, the excess mortality in TR seems to be 
independent of pulmonary hypertension and other 
concomitant clinical parameters, as recent studies 
suggest [13–17]. Therefore, it can be speculated 
that TV repair at an earlier disease stage might 
be favorable before irreversible right ventricular 
dysfunction and dilatation manifests [16, 18]. Such 
lessons were learned for the treatment of mitral 
valve regurgitation the past years. Because FTR 
is not only a marker for severity of HF disease, 
but also a major contributor in pathophysiological 
processes, it represents a potential therapeutic 
target in patients with HFrEF. Conversely, in-
hospital mortality of patients undergoing TV repair 
or replacement is substantial with reported rates 
between 8% and 24% [3, 12, 19, 20]. Older age 
(≥ 60 years) and TV replacement instead of repair 
can further double the risk for in-hospital death [3]. 
A novel treatment option for severe TR in 
patients with high surgical risk is a percutaneous 
tricuspid valve intervention, where the edge-to-
-edge-technique using the MitraClip® is most often 
used. A variety of transcatheter treatment options 
have been developed which simulate different surgi-
cal approaches like suture or ring annuloplasty (e.g. 
Trialign, TriCinch, and Cardioband or Millipede, 
respectively), coaptation enhancement (MitraClip, 
Forma, Pascal), valve replacement (e.g. NaviGate, 
TriSol, Cavi/BiCavi), or neochordae repair (e.g. 
Tricentro, TricValve) [21]. Most are still under inves-
tigation and are being tested in different phases of 
research. Recently published data from the TriValve 
registry showed significant clinical improvement 
and reduction of 1-year mortality after successful 
transcatheter tricuspid edge-to-edge repair [22].
However, appropriate patient selection for 
percutaneous TR repair is of crucial importance. 
Data on parameters and clinical constellations that 
translate into procedural success and favorable 
clinical outcome after transcatheter TV interven-
tion (TTVI) are limited.
The aim of this observational, prospective 
study was to analyze the clinical, echocardiograph-
ic, and procedural characteristics in patients with 
successful vs. unsuccessful percutaneous tricuspid 
intervention using the edge-to-edge technique.
Methods
Study design and patient population
All patients undergoing transcatheter TV 
repair at our institution were prospectively in-
cluded in our TV registry. Here, we report our 
first experiences with edge-to-edge repair using 
the MitraClip® between 12/2017 and 07/2019 
after starting this program in high-risk patients. 
All patients underwent standardized pre-, peri-, 
and post-procedural evaluation including clinical, 
echocardiographic and invasive examination. 
All parameters were prospectively entered into 
a database. All patients were discussed with 
the heart team and declined for conventional 
TV surgery. The safety and feasibility of the 
procedure, reduction of TR-grade, and clinical 
outcomes were collected and analyzed at the day 
of discharge and 30-day follow-up. Successful 
intervention was defined as successful edge-to- 
-edge repair using one or more MitraClips® with 
TR reduction of ≥ 1 grade and survival until 
hospital discharge.
The study was approved by the local ethics 
committee of the University Hospital of Jena (iden-
tification number: 2019-1325-BO) and conducted 
according to the principles of the Declaration of 
Helsinki.
Statistical analysis
All parameters were archived in a custom-
made database. Statistical calculations were done 
with SPSS (version 26.0, IBM SPSS statistics). 
Normal distribution was tested with the Shapiro-
-Wilks test. Continuous variables are expressed as 
mean ± standard deviation and analyzed with the 
unpaired Student t-test. Categorical variables are 
presented as counts (percentages) and analyzed 
with c2-test or Fisher’s exact test for small patient 
numbers. Statistical significance was assumed for 
p-values < 0.05 (two-tailed).
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Results
Baseline clinical characteristics
A total of 20 high-risk patients (78.6 ± 8.3 
years old, EUROScore II 9.1 ± 7.7%, Society of 
Thoracic Surgeons [STS] score 8.8 ± 4.3) with 
severe symptomatic TR were treated with the 
edge-to-edge technique using the MitraClip® sys-
tem. Baseline clinical characteristics are presented 
in Table 1. Most patients were in New York Heart 
Association (NYHA) functional status class III 
and showed chronic peripheral edema and pleural 
effusion before TTVI (Table 1). All but 1 patient 
had concomitant atrial fibrillation, and 18 (90%) 
patients showed pulmonary hypertension with 
a mean pulmonary pressure of 31.3 ± 7.5 mmHg. 
We found concomitant mitral regurgitation of grade 
≥ 2 in 11 (55%) patients. Overall, liver function 
was not reduced, and patients were on moderate 
dosage of diuretics (24.2 ± 15.6 mg torasemid 
equivalent dose). Cardiopulmonary exercise test 
(spiroergometry) could only be performed in 
8 (40%) patients due to advanced HF and the 
frailty of the patient population (exercise capacity 
59.1 ± 20.6 W, VO2 anaerobic threshold 9.1 ± 1.6, 
VO2 peak 11.6 ± 2.9). Cardiac index was ≤ 1.8 L/ 
/min/m2 in 4 (20%) patients. Concomitant percu-
taneous repair of the mitral valve, using the edge-
to-edge technique as well, was done in 2 (10%) 
patients before TTVI (Table 1).
Tricuspid regurgitation:  
Etiology and echocardiographic data
Left ventricular (LV) systolic function was 
mostly normal or mildly reduced (ejection fraction 
[EF] 54.3 ± 14.6%) and only 4 (20%) patients had 
a LVEF below 40% (Table 2). Conversely, 11 (55%) 
patients had a reduced right ventricle (RV) function 
with a RV fractional area change < 35% (Table 2). 
Our patient population showed a mean TR grade of 
3.9 ± 0.8 (median 4.0) using the new 5-stage grad-
ing scheme, with 13 (65%) patients suffering from 
massive or torrential TR (Table 2, Fig. 1A, B) [10]. 
The effective regurgitation orifice area (EROA), 
TR volume, and TR vena contracta are outlined 
in Table 2. The etiology of TR was judged as 
functional in 14 (70%) patients, structural in 
5 (25%) patients, and mixed in 1 (5%) patient. Of 
note, chronic pulmonary disease was only noted 
in 3 (15%) patients, and concomitant implantable 
cardioverter-defibrillator or pacemaker leads were 
detected in 3 (15%) patients (Table 1). The calcu-
lated mean TRuE risk score (https://thetruerisk.
com [23]) of 7.1 ± 2.3 (median 6.0) in our sample 
size represents a high risk (75th percentile) for 
5-year mortality and therefore a patient population 
with advanced TR disease.
TTVI: Procedural data, safety, and  
acute procedural success
Overall, TR clip procedure was safe without 
any major procedural complications such as emer-
gent surgery, cardiac tamponade, prolonged cardio-
pulmonary resuscitation, or myocardial infarction. 
The operator learning curve for TTVI has to be 
judged as steep. The procedure time of the first 
two TTVIs was 290 and 314 min, which is rather 
long. However, the subsequent procedure time 
shortened and ranged between 54 and 200 min 
with a mean of 138.2 ± 42.9 min (Table 2).
In total, 15 (75%) patients had a successful 
intervention. In 5 (25%) patients TTVI failed due 
to either unsuccessful clip implantation (n = 2), 
single leaflet device attachment (SLDA) before 
discharge (n = 1), or TR reduction < 1 grade 
(n = 1). One patient developed upper gastrointes-
tinal bleeding due to an esophageal Mallory-Weiss 
tear that needed endoscopic clip application after 
TTVI. However, there was no transfusion required. 
There was 1 death due to progressive cardiogenic 
shock 4 days after the procedure, but the proce-
dure was planned as the last therapeutic option in 
this terminally ill patient (n = 1, 5% in-hospital 
mortality).
A mean of 1.8 ± 0.8 clips were implanted per 
patient: in 14 (70%) patients clips were implanted 
into the anteroseptal commissure, in 2 (10%) 
patients solely in the posteroseptal commissure, 
whereas 3 (15%) patients received clipping of both 
antero- and posteroseptal commissures (Table 2, 
Fig. 2). TR grade was significantly reduced from 
stage 4.0 ± 0.8 at baseline to stage 2.5 ± 1.0 at 
discharge and 2.8 ± 0.8 at 30-day follow-up in all 
patients and particularly in patients with successful 
TTVI (Fig. 1A, B).
We did not see an association between clip 
location and success rate. However, the main jet 
location in patients with failed acute success was 
posteroseptal (n = 3, 60%; Table 2). Of note, in 
18 of 20 patients NTR MitraClips were implanted, 
and following the market launch of the new XTR 
clips the last 2 patients were successfully treated 
with XTR MitraClips.  
Patients showed similar comorbidities irre-
spective of procedural success (Table 1). However, 
patients with a failed TTVI seemed to be sicker 
because the LVEF was lower, diuretics equivalent 
doses were higher, renal function was worse, and 
www.cardiologyjournal.org 581
Sylvia Otto et al., Tricuspid annular geometry and percutaneous edge-to-edge tricuspid valve repair 
Table 1. Clinical characteristics of the patient population (n = 20) at baseline.
All patients  
(n = 20)
Acute success  
(n = 15)




Age [years] 78.6 ± 8.3 80.3 ± 5.2 73.4 ± 13.8 0.11
Male sex 10 (50%) 6 (39.9%) 4 (80%) 0.13
Body mass index [kg/m2] 27.2 ± 5.7 (27.2) 27.1 ± 6.2 (27) 27.2 ± 4.5 (27.4) 0.97
NYHA class: 0.015
II 2 (10%) 0 (0%) 2 (40%)
III 14 (70%) 11 (73.3%) 3 (60%)
IV 4 (20%) 4 (26.7%) 0 (0%)
Ejection fraction > 40% 16 (80%) 13 (86.7%) 3 (60%) 0.22
Edema 18 (90%) 13 (86.7%) 5 (100%) 0.42
Pleural effusion 10 (50%) 7 (46.6%) 3 (60%) 0.61
Ascites 8 (40%) 4 (26.7%) 4 (80%) 0.036
STS score 8.8 ± 4.3 (7.6) 8.4 ± 3.4 (7.9) 9.7 ± 6.9 (6.4) 0.58
EuroScore II 9.1 ± 7.7 (6.6) 9.3 ± 7.3 (7.4) 8.6 ± 9.8 (3.2) 0.87
Concomitant mitral clip 2 (10%)  2(13.3%) 0(0%) 0.42
Comorbidities
Atrial fibrillation 19 (95%) 15(100%) 4(80%) 0.08
Diabetes 6 (30%) 5(33.3%) 1(20%) 0.59
COPD 3 (15%) 3(19.9%) 0(0%) 0.30
Pacemaker/ICD 3 (15%) 2 (13.3%) 1(20%) 0.74
Previous cardiac surgery 3 (15%) 2(13.3%) 1(20%) 0.74
Pulmonary hypertension 18 (90%) 14(93.3%) 4(80%) 0.42
End stage renal failure  
requiring dialysis
2 (10%) 1(6.7%) 1(20%) 0.42
Coronary artery disease 5 (25%) 2 (13.3%) 3 (60%) 0.34
Co-medication
Torasemide equivalent  
dose [mg]
24.2 ± 15.6 (20) 20.7 ± 14.6 (20) 37.5 ± 12.6 (40) 0.052
Thiazide use 9 (45%) 6 (39.9%) 3 (60%) 0.24
MRA 4 (20%) 4 (26.7%) 0 (0%) 0.27
Oral anticoagulation 15 (75%) 13 (86.7%) 3 (60%) 0.21
Laboratory parameters
Creatinine [mg/dL]* 1.4 ± 0.4 (1.3) 1.34 ± 0.4 (1.28) 1.53 ± 0.6 (1.5) 0.46
BUN [mg/dL]* 77.8 ± 46.1 (71.9) 73.1 ± 37.1 (71.9) 93.4 ± 73.1 (90.1) 0.46
GFR [mL/min]* 45.2 ± 13.6 (43.1) 44.1 ± 12.0 (43.1) 49.2 ± 20.1 (50.3) 0.53
BNP [pg/mL] 826.7 ± 734.8 (540) 806.9 ± 657.2 (622) 886.2 ± 1023.2 (456) 0.84
Bilirubin [µmol/L] 15.3 ± 5.2 (15) 15.7 ± 5.2 (15) 14.4 ± 5.6 (14) 0.65
ASAT [µmol/L × s] 0.52 ± 0.22 (0.46) 0.54 ± 0.25 (0.48) 0.44 ± 0.13 (0.45) 0.42
ALAT [µmol/L × s] 0.29 ± 0.2 (0.22) 0.31 ± 0.21 (0.28) 0.21 ± 0.12 (0.17) 0.36
Cholinesterasis [µmol/L × s] 98.1 ± 31.2 (99) 102 ± 32.7 (103) 86.2 ± 25.5 (78) 0.35
Hemoglobin [mmol/L] 7.6 ± 0.8 (7.8) 7.5 ± 0.9 (7.6) 7.8 ± 0.4 (7.9) 0.24
Data are shown as mean ± standard deviation (median) or number (percentage). *Patients on dialysis were excluded from analysis of renal 
function parameters; NYHA — New York Heart Association; STS — Society of Thoracic Surgeons; COPD — chronic obstructive pulmonary 
disease; ICD — implantable cardioverter-defibrillator; MRA — mineralocorticoid receptor antagonists; BUN — blood urea nitrogen;  
GFR — glomerular filtration rate; BNP — B-type natriuretic peptide; ASAT — aspartate transaminase; ALAT — alanine aminotransferase
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more often there was evidence of ascites, peripher-
al edema, and pleural effusion, even though not all 
parameters reached significance in this relatively 
small patient group (Table 1). Conversely, patients 
with failed and successful TTVI had comparable 
scores on STS and EuroScore II, but most of the 
aforementioned parameters are not included in 
these standardized scores, and neither are those 
validated for single TV procedures. Interestingly, 
we found no differences regarding invasive hemo-
Table 2. Echocardiographic, invasive, and procedural characteristics of the patient population (n = 20).
All patients  
(n = 20)
Acute success  
(n = 15)




LVEF [%] 54.3 ± 14.6 (60.0) 56.8 ± 13.7 (60) 47.0 ± 16.7 (46) 0.203
RV FAC [%] 35.0 ± 6.3 (33.5) 35.1 ± 6.6 (33) 34.8 ± 6.1 (37.5) 0.95
TV annulus [mm] 45.5 ± 5.6 (45.0) 43.9 ± 4.6 (44) 50.0 ± 6.5 (50) 0.032
Coaptation depth [mm] 7.4 ± 3.2 (7.0) 6.7 ± 3.1 (6.8) 9.8 ± 2.6 (11) 0.056
Tenting area [cm2] 2.4 ± 1.0 (2.3) 2.1 ± 0.9 (2.14) 3.2 ± 1.0 (3.35) 0.025
TR vena contracta [mm] 11.5 ± 4.3 (10.0) 11.5 ± 4.2 (10) 12.6 ± 4.6 (12) 0.53
EROA [cm2] 0.73 ± 0.26 (0.76) 0.71 ± 0.28 (0.76) 0.78 ± 0.19 (0.80) 0.59
TR volume [mL/beat] 59.7 ± 19.5 (59) 58.6 ± 20.9 (59) 62.8 ± 15.9 (61) 0.68
TR grade at baseline (5 stages): 4.0 ± 0.8 (4) 3.9 ± 0.8 (4) 4.2 ± 0.8 (4) 0.45
Severe 7 (35%) 6 (40%) 1 (20%) 0.45
Massive 7 (35%) 5 (33.3%) 2 (40%)
Torrential 6 (30%) 4 (26.7%) 2 (40%)
Main jet location: 0.026
Central 11 (55%) 9 (60%) 2 (40%)
Anteroseptal 5 (25%) 5 (33.3%) 0 (0%)
Anteroposterior 0 (0%) 0 (0%) 0 (0%)
Posteroseptal 4 (20%) 1 (6.7%) 3 (60%)
Invasive hemodynamics
Systolic PP [mmHg] 49.2 ± 12.8 (50.5) 50.0 ± 12.3 (53) 46.8 ± 15.8 (45) 0.64
Mean PP [mmHg] 31.3 ± 7.5 (31.0) 31.3 ± 6.8 (32) 31.2 ± 10.2 (30) 0.99
Right atrial pressure [mmHg] 12.9 ± 5.6 (14.0) 12.6 ± 5.7 (12) 13.6 ± 5.6 (15) 0.74
PCWP [mmHg] 20.6 ± 5.6 (20.0) 20.9 ± 5.3 (20) 19.6 ± 7.1 (17) 0.68
CI [L/min/m2] 2.2 ± 0.5 (2.3) 2.2 ± 0.5 (2.2) 2.2 ± 0.3 (2.4) 0.92
Tricuspid valve intervention
Procedure duration [min] 170.0 ± 75.8 (150.5) 163.6 ± 65.6 (140) 127.4 ± 60.9 (114) 0.29
Fluoroscopy time [min] 18.8 ± 15.3 (15.4) 19.5 ± 13.3 (16.2) 17.1 ± 11.9 (12.1) 0.73
Total number of clips 1.8 ± 0.8 (2) 1.7 ± 0.6 (2) 1.4 ± 1.1 (1) 0.50
Clip position: 0.23
Anteroseptal 14 (70%) 10 (66.7%) 4 (20%)
Posteroseptal 2 (10%) 2 (13.3%) 0 (0%)
Both 3 (15%) 3 (20%) 0 (0%)
Bleeding requiring transfusion 2 (10%) 1 (6.7%) 1 (20%) 0.20
Acute renal failure 3 (15%) 2 (13.3%) 1 (20%) 0.73
New dialysis 1 (5%) 0 (0%) 1 (20%) 0.08
Data are shown as mean ± standard deviation (median) or number (percentage). LVEF — left ventricular ejection fraction; RV FAC — right 
ventricle fractional area change; TV — tricuspid valve; TR — tricuspid regurgitation; EROA — effective regurgitation orifice area; PP — pulmo-
nary pressure; PCWP — pulmonary capillary wedge pressure; CI — cardiac index
www.cardiologyjournal.org 583
Sylvia Otto et al., Tricuspid annular geometry and percutaneous edge-to-edge tricuspid valve repair 
dynamics and procedural aspects, as well as RV 
function (Table 2). There were no differences in 
conventional echocardiographic parameters for 
TR severity (vena contracta, EROA, TR grade, 
TR volume; Table 2). However, echocardiographic 
parameters describing tricuspid annulus geometry 
(TV annulus, coaptation depth, tenting area) were 
significantly larger in patients with failed TTVI 
(Table 2).
Clinical outcome at 30-day follow-up
The NYHA class improved significantly be-
tween baseline and 30-day follow-up, as outlined 
in Table 3 and Figure 3. At 30-day follow-up, 
SLDA with worsening of TR was observed in 
2 more patients, and 1 patient died due to worsen-
ing HF. Thus, the overall 30-day overall success 
rate was 60% (n = 12) and 30-day mortality was 
10% (n = 2). However, the deaths in this cohort 
were due to progressive and terminal HF despite 
TTVI rather than due to TTVI. Comparing pa-
tients at 30-day follow-up (30-day success, n = 12 
vs. 30-day failure, n = 8), we still observed no 
differences in conventional echocardiographic 
parameters as mentioned above. In line with the 
reported acute success data, tricuspid annulus ge-
Figure 1. A. Tricuspid regurgitation grade pre- and post-tricuspid valve intervention in the total patient population 
(n = 20); One patient died before discharge and another patient died within 30 days; B. Tricuspid regurgitation grade 
pre- and post-tricuspid valve intervention in patients with successful transcatheter tricuspid valve intervention at 
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Figure 2. Numbers of clips implanted per patient (left) and leaflet location of implanted clips (right).
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ometry parameters remained larger in the 30-day 
failure group (tenting area 2.0 ± 0.8 vs. 2.9 ± 1.1 cm2, 
p = 0.057; coaptation depth 6.1 ± 2.4 vs. 9.5 ± 
± 3.3, p = 0.016; TV annulus 44.6 ± 4.5 vs. 46.8 ± 
± 7.1, p = 0.412). Of note, in all patients (n = 3) with 
a transvalvular implanted lead (cardiac implantable 
electronic devices [CIED]) TTVI failed at 30-day 
follow-up (p = 0.02). 
Discussion
In this prospective cohort study, we analyzed 
clinical, procedural, and echocardiographic data 
on outcomes after TTVI using the edge-to-edge 
technique. With high initial implantation success 
(85%) and low in-hospital mortality rate (5%), this 
procedure is a promising alternative to surgical TV 
repair or replacement. While our observed 30-day 
success rate was 60% lower than that reported by 
other investigators (e.g. 86% in TRILUMINATE 
and TriValve, 81% by Besler et al. [24]), patient 
selection seems to play a pivotal role because 
we included patients with advanced (right-sided) 
HF [7, 24–26]. The high TRuE risk score of > 6 
in our cohort underlines this disease stage and 
a patient population at high risk [23]. 
The optimal timing for surgical or transcath-
eter TV repair remains unclear. RV and tricuspid 
annular remodeling progress with advanced TR 
stages and RV failure. Therefore, early TV inter-
vention during TR disease progression using the 
edge-to-edge technique has been suggested to 
reverse RV remodeling and failure. Echocardio-
graphic grading of TR severity is complicated and 
requires extensive operator training due to the 
complexity of the TV apparatus  and its challenging 
anatomy. Interestingly, we found no differences in 
“conventional” echocardiographic parameters for 
TR severity (vena contracta, EROA, TR grade, 
TR volume) with respect to short-term success. 
Recently, more sophisticated approaches involving 
qualitative, quantitative, and semi-quantitative 
criteria have been proposed. These data require 
further verification regarding their predictive 
power [7]. 
Moreover, identification of the main patho-
genic mechanism for TR might have prognostic 
implications [7]. A decade ago, Min et al. [27] 
demonstrated that the antero-posterior annulus 
diameter and tenting volume before tricuspid an-
nuloplasty were independent predictors of residual 
Table 3. Outcome parameters at discharge and 30-day follow-up in the overall patient population and 
comparing patients with acute clinical and procedural success versus acute failure.
All patients  
(n = 20)
Acute success  
(n = 15)
Acute failure  
(n = 5)
P
TR grade at discharge 2.5 ± 0.96 (2.0) 2.1 ± 0.5 (2.0) 4.0 ± 0.8 (4.0) < 0.001
TR grade at 30-day follow-up 2.8 ± 0.8 (2.5) 2.4 ± 0.4 (2.5) 4.0 ± 0.8 (4.0) < 0.001
In-hospital mortality 1 (5%) 0 (0%) 1 (20%) 0.99
30-day mortality 2 (10%) 1 (6.7%) 1 (20%) 0.42
Total hospital stay [days] 12.4 ± 7.5 (8.5) 11.5 ± 6.5 (9) 15.0 ± 10.1 (8) 0.37
ICU stay [days] 3.6 ± 3.9 (2.5) 3.6 ± 4.5 (2) 3.4 ± 1.8 (4) 0.90
SLDA 3 (15%) 2 (13.3%) 1 (20%) N/A
Time to SLDA [days] 26 ± 19.1 (37) 37.0 ± 0.0 (37) 4 N/A
Data are shown as mean ± standard deviation (median) or number (percentage); TR — tricuspid regurgitation; ICU — intensive care unit; 
SLDA — single leaflet device attachment
Figure 3. New York Heart Association (NYHA) class at 
baseline and 30-day follow-up in the total patient popu-
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TR after surgical correction. Our data underline 
this observation. We show differences in tricuspid 
annulus geometry expressed as TV annulus diam-
eter, coaptation depth, and tenting area, which were 
all significantly larger in the patients with failed 
percutaneous edge-to-edge repair of TV. However 
geometric changes of the TV apparatus seem to be 
an indicator of severity of TR. Therefore, coapta-
tion enhancement strategies like the edge-to-edge 
technique might be a feasible approach during 
mid-stage TR disease. Conversely, advanced TR 
disease is characterized by progressive annular 
dilatation, RV remodeling, and leaflet tethering, 
which then result in geometric abnormalities of the 
TV apparatus. In light of this, combined approaches 
with additional annuloplasty or TV replacement 
strategies might be the preferable treatment op-
tion for later stages of TR. On the other hand, 
there might be “a point of no return” during TR 
disease progression, reflecting the underlying left 
and/or right HF. As we know from the published 
trials COAPT and MITRA-FR for percutaneous 
treatment of functional mitral regurgitation, valve 
regurgitation needs also to be graded and judged 
with respect to atrial and ventricular dimensions 
and function [28, 29].
In our patient cohort, TTVI failed in most pa-
tients with the main jet located non-centrally and 
non-anteroseptally (success rate 25%, 1 out of 4). 
However, jet location can be verified as a predictor 
for procedural outcome of the edge-to-edge repair 
and is in agreement with previously published data 
[22, 24]. Only 3 of our patients (15%) had a CIED, 
compared to 26% in the TriValve registry. However, 
all 3 CIED patients failed TTVI at 30-day follow-up, 
which is contrary to the reported success rate of 
78.6% in the TriValve cohort [30]. This difference in 
outcome might be related to our sample size or pos-
sibly due to patient selection. The main jet location 
in the TriValve registry was in the favorable central/ 
/anteroseptal location in CIED patients, which is 
contrary to our CIED patients [30]. 
Comparing our patient data with those of 
a previously published large cohort study on FTR, 
there are distinct differences regarding the patient 
population [13]. Contrary to Benfari et al. [13], our 
cohort is of mixed nature regarding LV function 
including both HFrEF and HF with preserved 
ejection fraction patients. Moreover, we found 
atrial fibrillation in all of our patients compared to 
only 48% of the severe FTR patients in the Benfari 
cohort. Atrial fibrillation is seen as a major con-
tributor to FTR and is strongly related to severe 
FTR because it can lead to right atrium and thus 
annulus dilation even in the absence of pulmonary 
hypertension [31, 32]. However, because FTR is 
related to a variety of cardiac dysfunction, detailed 
classification of associated TR pathology, especially 
for the group of functional TR, and studies on 
therapeutic options with respect to the origin of 
TR disease are needed. On the other hand, studies 
on surgical TR repair could show that survival is 
not affected by the cause of TR but rather by HF 
stage and comorbidities [18]. 
Some studies reported excess mortality for 
FTR as a result of underlying pulmonary hyperten-
sion and/or right/left HF [33–35]. This concept has 
been challenged in the past years, because several 
studies could show that FTR is an independent 
predictor for survival [13, 16, 17]. This calls not 
only for a specific treatment of TR but also for an 
effort on early identification of FTR patients; in 
particular, if other cardiac pathologies such as atrial 
fibrillation are present with the resulting need for 
close clinical monitoring.
Limitations of the study
This is an observational, prospective cohort 
study reporting a single-center experience with 
a small sample size and multiple comparisons. Thus, 
patient bias and significances appearing by chance 
cannot be excluded completely. The findings of our 
study have to be judged as hypothesis-generating 
and should be verified by further studies. However, 
the overall available patient population for isolated 
TV procedures is limited. In other studies, such as 
the recently published Triluminate registry, an aver-
age of only 4 patients per study site was included 
during a comparable time period [25].
Conclusions
Our data suggest the significance of tricuspid 
annulus geometry, which seems to impact short-
-term outcomes after percutaneous edge-to-edge 
repair of TR. Further investigations and possibly 
more sophisticated interventional approaches in-
volving the tricuspid annulus are needed to better 
understand and treat this complex valve disease.
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